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IL-10 inhibits a broad spectrum of cellular 
  immune responses. It suppresses the function of 
APCs and T cells by inhibiting proinfl  ammatory 
cytokine production, co-stimulation, MHC class 
II expression, and chemokine secretion (1, 2). 
IL-10 has been associated with immunopathol-
ogy in various immune-mediated and infl  amma-
tory diseases. For example, treatment with a 
combination of anti–IL-10R monoclonal anti-
body and Toll-like receptor 9 (TLR9) ligands 
had potent therapeutic antitumor eff  ects (3, 4), 
indicating a role for IL-10 in the pathogenesis 
of cancer.
Viruses use a variety of strategies to avoid rec-
ognition by the host immune system (5–7). The 
active induction of immune suppression is one 
mechanism by which viruses escape clearance and 
thus establish a persistent infection (8). In humans, 
chronic viral infections affl   ict millions of people 
worldwide (9–11). Interestingly, elevated levels 
of IL-10 production have been associated with 
persistent infection by hepatitis C virus (HCV) 
(12, 13), HIV (14–18), and Epstein-Barr virus 
(1, 19). It was recently reported that upon HCV 
infection, intrahepatic CD8+ T cells from persis-
tently infected subjects suppressed the in vitro 
proliferative responses of liver-derived lympho-
cytes in an HCV-specifi  c and IL-10–dependent 
manner (20). Moreover, both CD4+ and CD8+ 
T cells have been shown to express high levels of 
IL-10 in HIV-infected individuals (14, 15). In ad-
dition, a higher frequency of IL-10–producing 
CD4+ T cells was observed in HIV-infected 
  individuals with progressive disease or active 
HIV replication compared with individuals in the 
  latent phase of disease (16–18).
To gain further insight into the role of IL-10 
in the establishment and maintenance of persis-
tent viral infections, we investigated whether 
this cytokine is involved in the persistence of 
lymphocytic choriomeningitis virus (LCMV) 
infection in its natural host, the mouse. LCMV 
is an arena virus that can cause either acute or 
persistent infection in vivo depending on the 
strain, route of infection, and dose of virus (21). 
Although adult mice infected with LCMV 
Armstrong rapidly clear the infection and 
  establish a stable memory T cell pool (22–27), 
infection with a naturally selected isolate of 
LCMV Armstrong, the LCMV variant clone 
13, results in a prolonged infection that persists 
(28–30). This chronic infection is associated 
with the functional impairment, exhaustion, 
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and deletion of virus-specifi  c CD8+ T cells (31, 32), resulting 
in viral persistence, which was recently linked to expression of 
the programmed death 1 receptor (PD-1), an inhibitory re-
ceptor of the CD28 family (33–36).
DCs, which are key regulators of immune responses, play 
an important role in clearing viral infections. Upon engage-
ment of DCs, naive Th cells polarize into IFN-γ–producing 
Th1 or IL-4–producing Th2 eff  ector cells (37, 38). It has 
previously been suggested that diff  erent DC subsets, for ex-
ample CD11c+CD8α− and CD11c−CD8α+ DCs, have the 
potential to diff  erentially induce Th2 and Th1 cells, respec-
tively (39–41). Others have previously reported that, after 
LCMV clone 13 infection, LCMV-specifi  c CD4+ T cells 
from TCR transgenic SMARTA mice produced higher lev-
els of IL-10 than after LCMV Armstrong infection (42). In 
this study, we demonstrate that production of IL-10 during 
LCMV clone 13 infection is associated with viral persistence, 
because blockade of the receptor for IL-10 restored the anti-
viral immune response and resulted in viral clearance. This 
rapid resolution of viral infection after anti–IL-10R treat-
ment was associated with diminished levels of endogenous 
IL-10 production and enhanced antiviral CD8+ T cell re-
sponses. Further analysis revealed that viral persistence during 
LCMV clone 13 infection was linked to a decline in the 
number of CD11c+CD8α+ DCs.
CD11c+CD8α− DCs effi   ciently induced IL-10 secretion 
by antiviral CD4+ T cells, preventing viral clearance and there-
fore enabling viral persistence. Therapeutic IL-10R blockade 
broke the cycle of IL-10–mediated immune suppression, 
preventing IL-10 priming by CD8α− DCs and enhancing 
antiviral responses, thereby resolving infection in persistently 
infected mice.
These results highlight for the fi  rst time the role of IL-10 in 
the suppression of an antiviral immune response during a per-
sistent viral infection. Upon blockade of signaling through the 
IL-10R, secretion of IL-10 was almost completely abrogated. 
We therefore propose that IL-10R blockade may be of thera-
peutic benefi  t in the treatment of chronic viral infections.
RESULTS
Persistent infection with LCMV clone 13 is associated 
with increased IL-10 production
Previous studies reporting IL-10 production during chronic 
viral infections prompted us to examine the secretion of IL-
10 during chronic and acute LCMV infections (1, 12–19). 
Splenocytes from mice infected with LCMV clone 13 or 
LCMV Armstrong were isolated at various time points after 
infection and cultured for 48 h in the absence of exogenous 
antigen (to allow for direct ex vivo presentation of viral anti-
gens by splenic APCs). At the end of this culture period, we 
measured the concentration of IL-10 in the supernatants by 
ELISA. IL-10 production by splenocytes from mice infected 
with LCMV (both clone 13 and Armstrong strains) peaked 
at day 20 after infection (Fig. 1 A). However, splenocytes 
from mice infected with LCMV Armstrong secreted signifi  -
cantly less IL-10. This diff  erence was apparent regardless of 
the initial dose of virus, as increasing the inoculum of LCMV 
Armstrong from 105 PFU to 2 × 106 PFU resulted in com-
parable kinetics of IL-10 secretion (unpublished data). By day 
40, although IL-10 production was undetectable in LCMV 
Armstrong–infected mice, mice infected with LCMV clone 
13 still produced signifi  cant amounts of this cytokine (Fig. 
1 A). After in vitro LCMV clone 13 infection, we observed 
that IL-10 was produced by diff  erent immune cell types, in-
cluding CD4+ and CD8+ T cells and CD11c+ DCs, whereas 
LCMV Armstrong infection induced less IL-10 production 
by CD4+ T cells and CD11c+ DCs and none by CD8+ T 
cells (Fig. 1 B). Interestingly, when splenic cell cultures were 
treated with a neutralizing anti–IL-10R monoclonal anti-
body (which specifi  cally targets the IL-10R α chain) at the 
time of LCMV clone 13 infection in vitro, the levels of IL-10 
produced by CD4+ T cells were reduced to those found in 
LCMV Armstrong–infected mice (Fig. 1 B).
We then analyzed in vivo IFN-γ secretion by CD8+ T 
cells at diff   erent time points after LCMV Armstrong and 
LCMV clone 13 infection (Fig. 1 C). Interestingly, CD8+ T 
cells from LCMV clone 13–infected mice secreted IFN-γ 
only during the early phase of infection (day 5), at a time 
when no IL-10 was yet detected (Fig. 1 A). However, IFN-γ 
secretion was almost completely lost at later time points, and 
high levels of IL-10 were produced (Fig. 1, A and C). In 
contrast, IFN-γ production by CD8+ T cells from LCMV 
Armstrong–infected mice peaked later (day 7) and was 
  sustained in the form of a memory response (Fig. 1 C) (27). 
Secretion of TNF-α followed a similar profi  le (unpublished 
data). Increasing the dose of LCMV Armstrong did not in-
duce earlier cytokine responses (unpublished data). These re-
sults indicate that LCMV clone 13 induces a faster antiviral 
response, possibly linked to a higher binding affi   nity of the 
virus to its α-dystroglycan receptor (43).
It has recently been shown that high expression of PD-1 
is a characteristic of exhausted CD8+ T cells in LCMV clone 
13–infected mice and that treatment with anti–PD-1 anti-
bodies leads to the proliferation of antiviral T cells and the 
enhancement of viral clearance (33–36). We therefore ana-
lyzed PD-1 expression on T cells. We found that a small per-
centage of CD4+ and CD8+ T cells expressed PD-1 in naive 
mice (Fig. 1 D). Upon LCMV infection, signifi  cantly higher 
levels of PD-1 were expressed on CD8+ T cells isolated from 
LCMV clone 13–infected mice compared with LCMV Arm-
strong–infected mice (Fig. 1 D). In addition, the mean fl  uo-
rescence intensity of PD-1 was increased in T cells from 
LCMV clone 13–versus LCMV Armstrong–infected mice 
(unpublished data).
Based on these fi  ndings, we hypothesized that the im-
mune suppression mediated by LCMV clone 13 infection was 
caused by a shift from antiviral IFN-γ production to the se-
cretion of the immunosuppressive cytokine IL-10. To inves-
tigate whether IL-10 was directly involved in the suppression 
of the antiviral immune response, we infected IL-10–defi  cient 
(IL-10−/−) mice with LCMV clone 13 and monitored viral 
clearance. 3 wk after LCMV clone 13 infection, we found JEM VOL. 203, October 30, 2006  2463
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that viral titers were signifi  cantly lower in liver and kidney 
from IL-10−/− mice compared with wild-type control mice 
when measured by a highly sensitive RT-PCR method 
(Fig. 1 E). Resolution of LCMV clone 13 infection in IL-
10−/− mice was associated with a lower systemic IL-10 to 
IFN-γ ratio, as one would expect (Fig. 1 F). Sustenance of 
antiviral immune responses to clone 13 through genetic elim-
ination of IL-10 has been described in detail in another study 
by Brooks et al. (44).
Anti–IL-10R antibody therapy decreases viral titers 
and leads to disease amelioration
IL-10 can inhibit immune responses by skewing the develop-
ment of helper T cells and suppressing their function (45, 46). 
Based on our initial fi  ndings that cells from LCMV clone 13–
infected mice secreted IL-10 and that mice defi  cient in IL-10 
cleared this strain of LCMV more effi   ciently, we investigated 
whether blocking the IL-10–IL-10R signaling pathway could 
resolve LCMV clone 13–induced immune suppression and 
reestablish an antiviral Tc1/Th1 response. We therefore in-
fected BALB/c mice with LCMV clone 13 and injected 
age-matched groups with either a neutralizing anti–IL-10R 
monoclonal antibody or an IgG1 isotype control antibody on 
days 0, 7, and 14, or with a therapeutic regimen on days 7 and 
14 after infection. Disease severity was monitored by assessing 
bodyweight, spleen cell numbers, and viral titer over time. 
LCMV clone 13–infected mice treated with isotype control 
antibody lost body mass and weighed 30–40% less than 
age-matched naive mice (Fig. 2, A and C). These mice also 
exhibited a nonshiny, scruff  y coat (unpublished data). In 
comparison, LCMV clone 13–infected mice treated with 
anti–IL-10R antibody lost weight less rapidly (Fig. 2 A) and 
exhibited a healthy shiny coat (not depicted). In addition, we 
monitored viral loads in lymphoid and nonlymphoid organs 
isolated from persistently infected mice treated with anti–IL-
10R or IgG1. Viral titers were measured by conventional 
plaque assay (not depicted) and by a more recently developed, 
highly sensitive RT-PCR method (Fig. 2 B). At 6 and 26 wk 
after infection, numbers of LCMV genomic copies were low 
or nondetectable when measured by the sensitive RT-PCR 
method in organs from anti–IL-10R–treated mice; 36 wk af-
ter infection, viral titers remained undetectable in liver and 
kidney (Fig. 2 B). In contrast, viral genome copies were still 
detectable in these organs when mice were treated with IgG1 
isotype antibody, indicating that resolution of chronic in-
fection resulted from anti–IL-10R treatment rather than 
Figure 1.  Time course of T cell cytokine production after infection 
with LCMV clone 13: the role of IL-10 in promoting viral persis-
tence. (A) Spleen cells were isolated from BALB/c mice on days 0, 5, 7, 14, 
20, 40, and 94 after infection with 105 PFU LCMV Armstrong or 2 × 106 
PFU LCMV clone 13 and cultured for 48 h. The concentration of IL-10 
present in the culture supernatants was measured by ELISA. Data are 
plotted as IL-10 (pg/ml) produced per 106 cells and are means of three 
mice per time point. The experiment is representative of three similar 
experiments. (B) To reveal the origin of IL-10–producing cell subsets, 
BALB/c splenocytes were isolated and infected in vitro for 48 h with LCMV 
Armstrong or LCMV clone 13 without or with anti–IL-10R antibody treat-
ment (multiplicity of infection = 3). Next, CD4+, CD8+, and CD11c+ cells 
were enriched using MACS beads, and the supernatant of the purifi  ed 
populations was analyzed for IL-10 production by ELISA. The graph indi-
cates the levels of IL-10 (pg/ml) in the supernatant of CD4+, CD8+, and 
CD11c+ cells. Data are representative of one experiment with fi  ve mice 
per group. (C) Sensitive direct in vivo intracellular cytokine assay was 
performed to detect in vivo cytokine expression in LCMV-specifi  c T cells, 
as described by Liu et al. (reference 61). In brief, mice were injected i.v. 
with 0.5 mg BFA on days 5 and 7 after infection with 105 PFU LCMV Arm-
strong or 2 × 106 PFU LCMV clone 13. Spleens were harvested 6 h after 
BFA injection, and direct in vivo intracellular cytokine detection was per-
formed after staining with fl  uorescent antibodies to CD4, CD8, IFN-γ, and 
TNF-α. Mean values per spleen of three to fi  ve individual mice are shown. 
The experiment is representative of two similar experiments. (D) PD-1 
expression was detected on CD4+ and CD8+ T cells from naive or day 7 
LCMV Armstrong– or LCMV clone 13–infected mice by labeling spleno-
cytes with fl  uorescent antibodies to CD4, CD8, and PD-1. Percentages of 
PD-1–expressing T cells are shown. Data show one representative mouse 
per group (three mice total per group). (E) IL-10−/− and wild-type mice 
were infected with 2 × 106 PFU LCMV clone 13, and viral titers were de-
tected in kidney and liver from three mice per group by RT-PCR 3 wk after 
infection. Data are shown as mean LCMV genome copies per mg organ ± 
SEM. (F) Cytokine expression was monitored in wild-type and IL-10−/− 
mice 7 d after LCMV clone 13 infection by intracellular cytokine staining. 
Splenocytes were stimulated with BFA and GP33-41 or GP61-80 peptide for 
6 h. Intracellular cytokine detection was performed by staining with fl  uo-
rescent antibodies to CD4, CD8, IFN-γ, and TNF-α. The IL-10/IFN-γ ratio 
of CD4+ and CD8+ T cells is shown as mean values of three individual 
mice per group. Statistical analysis was performed using the Student’s t test. 
*, P < 0.01; **, P < 0.001; and ***, P < 0.0001.2464  IL-10R BLOCKADE RESOLVES CHRONIC VIRAL INFECTION | Ejrnaes et al.
  progressive viral elimination over time. Viral titers in organs 
from control IgG1-treated mice remained high, and virus pre-
dominated in the kidney, characterizing the chronic infec-
tion (Fig. 2 B). Furthermore, extremely low viral titers were 
  detected by LCMV plaque assay in kidney, liver, and lung 
6 wk after LCMV clone 13 infection in anti–IL-10R–treated 
Figure 2.  Clearance of virus in LCMV clone 13–infected mice 
treated with anti–IL-10R antibody. 6-wk-old BALB/c mice were infected 
with 2 × 106 PFU LCMV clone 13 and treated i.p. with 250 μg of a neutral-
izing anti–IL-10R antibody or an IgG1 isotype control antibody on days 0, 7, 
and 14 (A and B) or days 7 and 14 after infection (C). (A) Disease severity 
was evaluated by measuring the body weight of naive mice and LCMV clone 
13–infected mice injected with anti–IL-10R antibody or IgG1 isotype control 
antibody. Mice were monitored daily and weighed every third day. Data show 
mean body weight (in grams) ± SEM per group (n = 5) over time and are 
representative of fi  ve experiments (25 mice total per group). (B) Quantitative 
real time PCR for LCMV genome copies was performed on the cDNA ob-
tained by reverse transcription in quick-frozen organs from LCMV clone 
13–infected mice treated with IgG1 isotype control or anti–IL-10R antibody. 
Liver (left) and kidney (right) were harvested 1, 3, 6, 26, and 36 wk after in-
fection, and viral titers were measured by quantitative RT-PCR. Quantitative 
analysis was performed using the GraphPad Prism linear regression method. 
Histogram bars represent means values ± SD for four to six mice per group. 
The experiment is representative of fi  ve similar experiments. (C) Disease 
severity was evaluated by measuring body weight as described in A in mice 
treated therapeutically with anti–IL-10R antibody or IgG1 isotype control 
antibody on days 7 and 14 after LCMV clone 13 infection. Data show mean 
body weight (in grams) ± SEM per group (n = 5) over time and are repre-
sentative of two experiments (25 mice total per group). Statistical analysis 
was performed using the Student’s t test. **, P < 0.001; and ***, P < 0.0001.JEM VOL. 203, October 30, 2006  2465
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mice, and no virus was detected 26 wk after infection 
  (unpublished data).
Importantly, we also administered anti–IL-10R antibody 
in a therapeutic setting at days 7 and 14 after infection during 
the onset of lymphopenia and weight loss (by day 7 after in-
fection, the total number of splenocytes was reduced by 41% 
in LCMV clone 13–infected mice compared with naive 
mice; unpublished data). Anti–IL-10R treatment was thera-
peutically eff   ective during established infection as treated 
mice lost weight less rapidly (Fig. 2 C), did not exhibit any 
overt signs of disease, and showed a substantial reduction in 
viral titers in the liver, lung, and kidney 11 wk after treatment 
(not depicted). Additionally, a two to three log reduction in 
viral titer was observed when anti–IL-10R was given on days 
5 and 12 after LCMV clone 13 infection, as well as on days 
10 and 17 after infection (unpublished data).
Interestingly, there was no diff   erence in anti-LCMV–
  specifi   c antibody production after anti–IL-10R treatment 
(unpublished data), indicating that viral clearance was the 
  result of an enhancement of the antiviral T cell responses. 
These results demonstrate that blocking IL-10 signaling 
  results in clearance of an otherwise protracted LCMV clone 
13 infection. Notably, anti–IL-10R treatment was eff  ective even 
when given therapeutically during established infection.
Anti–IL-10R treatment of persistently infected mice 
restores antiviral CD8+ T cell responses
As reported previously (31, 47), we found that chronic infec-
tion was associated with deletion of virus-specifi  c CD8+ T 
cells, leading to a drastic decrease in the number of spleen 
cells (unpublished data). We discovered that this state of lym-
phopenia was reversed after anti–IL-10R therapy both when 
treatment was initiated at day 0 or therapeutically at day 7 af-
ter infection (Fig. 3 A). In addition, endogenous IL-10 pro-
duction by splenocytes isolated 3 wk after LCMV clone 13 
infection was signifi  cantly reduced in anti–IL-10R–treated 
mice, indicating that early blockade of this cytokine pre-
vented the long-term immunosuppressive eff  ects mediated 
by LCMV clone 13 infection (Fig. 3 B).
We therefore assessed the eff  ect of anti–IL-10R treatment 
on the LCMV-specifi  c T cell response in detail. Splenocytes 
from anti–IL-10R– and control IgG1–treated BALB/c 
mice were isolated at various time points after LCMV 
clone 13 infection and stimulated with the MHC class I–
  restricted immunodominant LCMV peptide NP118-126. The 
number of IFN-γ–secreting CD8+ cells was measured by 
  intracellular cytokine staining. Anti–IL-10R–treated mice 
had signifi  cantly higher numbers of IFN-γ–secreting CD8+ 
T cells compared with IgG1-treated mice, particularly at later 
time points (Fig. 3 C). Importantly, therapeutic treatment 
with anti–IL-10R on days 7 and 14 after LCMV clone 13 in-
fection caused a similar enhancement of the LCMV-specifi  c 
memory T cell response (Fig. 3 C). Thus, anti–IL-10R treat-
ment resulted in reemergence of a potent antiviral IFN-γ+ 
CD8+ T cell response, indicating that events occurring early 
during T cell responses can profoundly aff  ect the quality of 
T cell memory. It will be diffi   cult to determine whether the 
enhancement of viral-specifi  c CD8+ T cell responses was the 
cause or consequence of reduced viral loads; however, we 
believe that both alternatives are possible.
Finally, we investigated the eff  ect of anti–IL-10R treat-
ment on the PD-1 inhibitory pathway (33–36). To deter-
mine whether suppression of the PD-1 pathway could be 
involved in the enhancement of viral clearance after thera-
peutic anti–IL-10R treatment, we monitored expression of 
PD-1 by T cells in anti–IL-10R– and IgG1-treated mice 90 d 
after LCMV clone 13 infection. Low levels of PD-1 expres-
sion were detected on T cells from naive mice (Fig. 3 D, 
top). In comparison, T cells from LCMV clone 13–infected 
mice treated with IgG1 isotype antibody exhibited as much as 
a 25-fold induction of PD-1 expression compared with naive 
mice (Fig. 3 D, bottom). Importantly, a threefold reduction 
of PD-1 expression was observed on T cells from anti–IL-
10R–treated mice compared with IgG1-treated mice (Fig. 
3 D, middle). These results indicate that anti–IL-10R treat-
ment decreased PD-1 expression on T cells, which could po-
tentially contribute to abrogation of T cell exhaustion because 
treatment with anti–PD-1 antibodies in chronically infected 
mice has been shown to down-regulate PD-1 and circum-
vent virally induced CD8+ T cell exhaustion (33–36).
Anti–IL-10R treatment reverses lymphopenia 
in LCMV clone 13–infected mice
To further investigate the eff  ect of anti–IL-10R treatment on 
the LCMV-specifi  c immune response, we examined absolute 
numbers of diff  erent splenic cell subsets over time in mice 
infected with LCMV clone 13 and treated with anti–IL-10R 
or control IgG1 antibody. We discovered that even though 
LCMV clone 13 infection caused a reduction in the numbers 
of cells present in the spleen at day 21 after infection regard-
less of treatment, by day 150 after infection the numbers of 
CD4+, CD8+, B220+, and CD11c+ cells in anti–IL-10R–
treated mice were similar to those in naive  mice, whereas in 
IgG1-treated mice these cells remained scarce (Fig. 4 A). No-
tably, the numbers of CD11b+ cells in the spleen at day 150 
after infection were comparable between groups, suggesting 
that the decrease in viral titers after anti–IL-10R treatment 
was not solely caused by enhanced clearance of virally 
infected macrophages.
CD8𝗂+ DCs are eliminated after LCMV clone 13 
but not LCMV Armstrong infection
We hypothesized that the loss of antiviral T cells after LCMV 
clone 13 infection would be mediated by APCs. DCs are the 
most potent APCs and have been shown to play a crucial role 
in the priming of LCMV-specifi  c cytotoxic T cells (48). We 
therefore examined absolute numbers of diff  erent DC subsets 
(CD11c+CD8α− and CD11c+CD8α+) and their ratio after 
infection with LCMV Armstrong or LCMV clone 13. Over 
the course of infection, the number of CD8α− and CD8α+ 
DCs increased in LCMV Armstrong–infected mice but re-
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(Fig. 4 B). In contrast, although the number of CD8α− DCs 
from LCMV clone 13–infected mice 6 wk after infection was 
also comparable to that of naive mice, CD8α+ DCs gradually 
disappeared over time (Fig. 4 B). It has been previously shown 
that >50% of CD11c+ DCs carry viral particles at this time 
point in clone 13–infected mice (49), making these cells an 
excellent target for destruction and elimination by the im-
mune system. In contrast, very few CD11c+ cells are infected 
at the same time point after LCMV Armstrong infection (49). 
Importantly, the numbers of CD8α+ DCs were signifi  cantly 
lower in LCMV clone 13–infected mice 6 wk after infection 
compared with mice infected with  LCMV Armstrong (Fig. 
4 B). Because the CD8α+ DC subset declined in LCMV 
clone 13–infected mice and the CD8α− DC subset remained 
at a stable level, the CD8α− to CD8α+ DC ratio was skewed 
toward CD8α− DCs 6 wk after infection (Fig. 4 C). To 
  investigate whether this phenomenon was aff  ected by thera-
peutic anti–IL-10R treatment, absolute numbers of CD8α− 
and CD8α+ DCs were monitored 6 wk after LCMV clone 
13 infection in mice treated with anti–IL-10R on days 7 and 
14 after infection. Anti–IL-10R treatment decreased CD8α− 
DC numbers more than twofold, as well as CD8α+ DC 
numbers to a lesser extent (Fig. 4 B). Hence, the resulting 
CD8α− to CD8α+ DC ratio after anti–IL-10R treatment re-
sembled the ratio in LCMV Armstrong–infected mice 6 wk 
after infection (Fig. 4 C). In summary, these fi  ndings show 
that anti–IL-10R treatment in LCMV clone 13–infected 
mice resulted in a skewing of the CD8α− to CD8α+ DC 
  ratio to levels seen in mice infected with the nonpersistent 
LCMV Armstrong strain.
Figure 3.  Anti–IL-10R antibody treatment in LCMV clone  
13–infected mice increases total cell numbers, decreases IL-10 
production, induces a functional antiviral memory T cell pool, and 
reduces the percentage of PD-1–expressing T cells. (A) 6-wk-old 
BALB/c mice were infected with 2 × 106 PFU LCMV clone 13 and 
treated with an IgG1 isotype control antibody or i.p. with 250 μg of 
a neutralizing anti–IL-10R antibody on days 0, 7, and 14 (left) or with a 
therapeutic regimen on days 7 and 14 after LCMV clone 13 infection 
(right). On days 20 and 150 after LCMV infection, spleen cells were iso-
lated and counted. Histogram bars represent mean values ± SD for 
three mice per group. The experiment is representative of three similar 
experiments. (B) Splenocytes from naive mice, LCMV clone 13–infected 
mice treated with IgG1, or anti–IL-10R antibody on days 0, 7, and 14 
were isolated 3 wk after infection and cultured for 48 h. The amount of 
IL-10 present in the culture supernatant was measured by ELISA. Data 
are plotted as IL-10 (pg/ml) produced per 106 cells and are means of 
three mice per time point. Results are representative of three identical 
experiments. (C) Splenocytes from LCMV clone 13–infected BALB/c mice 
treated with IgG1 or anti–IL-10R antibody on days 0, 7, and 14 (left) or 
day 7 and 14 (right) were isolated at day 20 (early memory) and 150 
(late memory) after infection. Cells were stimulated in the presence of 
NP118-126 peptide and BFA for 5 h. Intracellular cytokine staining was 
performed using fl  uorescent antibodies to CD8 and IFN-γ. The numbers 
of IFN-γ+CD8+ T cells per spleen are shown. Histogram bars represent 
mean values ± SD for three mice per group. The experiment is repre-
sentative of three similar experiments. (D) BALB/c mice were treated 
with anti–IL-10R antibody or IgG1 isotype control antibody on days 7 
and 14 after LCMV clone 13 infection. 90 d after infection, percentages 
of PD-1–expressing splenic CD4+ and CD8+ T cells were analyzed by 
gating on CD4+ (left) and CD8+ T cells (right) and staining for PD-1. 
Numbers in dot plots represent percentages of CD4+ and CD8+ T cells 
expressing PD-1. Data show one representative mouse per group 
(four mice total per group). Statistical analysis was performed using 
the Student’s t test. *, P < 0.01; **, P < 0.001; and ***, P < 0.0001.JEM VOL. 203, October 30, 2006  2467
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CD8𝗂− DCs preferentially prime IL-10 production during 
the development of chronic infection
Previous reports suggest that diff  erent DC subsets vary in 
their ability to prime eff  ector T cells (39, 50, 51). In particu-
lar, evidence suggests that diff  erent DC subsets can induce 
T cells to produce diff  erent cytokines depending on the cy-
tokine milieu in which they encounter antigen (40, 41, 46). 
We therefore investigated whether T cell priming by diff  er-
ent DC subsets modulated the nature of the antiviral T cell 
response. CD11c+CD3− splenic DCs were isolated from 
mice infected 7 d earlier with LCMV Armstrong or LCMV 
clone 13. In addition, one group of mice was treated with 
anti–IL-10R antibody at the time of infection. CD11c+CD3− 
DCs from all groups were sorted into CD8α− and CD8α+ 
DC subsets on day 7 after infection (Fig. 5). This early time 
point was chosen to allow for capture and processing of viral 
antigens by DCs directly in vivo during the early phase of 
LCMV Armstrong and LCMV clone 13 infection, which is 
Figure 4.  Anti–IL-10R treatment restores cell numbers in LCMV 
clone 13–infected mice and resets the CD8𝗂− versus CD8𝗂+ DC 
ratio to levels observed in LCMV Armstrong–infected mice. (A) The 
effect of 250 μg anti–IL-10R antibody (i.p.) or IgG1 isotype control antibody 
treatment on different splenic cell subsets was monitored quantitatively. 
Spleens of mice infected 3 or 21 wk earlier with LCMV clone 13 were har-
vested, and cell suspensions were stained with fl  uorescent antibodies to 
CD4, CD8, B220, CD11c, and CD11b. Age-matched naive mice were included 
as controls. Numbers of cells were quantifi  ed by relating the percentage 
to total numbers of spleen cells. Mean values for three to fi  ve individual 
mice are shown. Results are representative of three similar experiments. 
(B and C) The total numbers of CD11c+CD8α− (B, top) or CD11c+CD8α+ 
splenic DC subsets (B, bottom) and the CD8α− to CD8α+ DC ratios (C) were 
 determined  0,  1, 2, and 6 wk after LCMV Armstrong or LCMV clone 13 in-
fection. In addition, absolute splenic DC subsets (B) and the CD8α− to 
CD8α+ DC ratio (C) were calculated from mice therapeutically treated with 
anti–IL10R on days 7 and 14 after LCMV clone 13 infection; the latter was 
examined at 6 wk after infection only. Cell suspensions were prepared by 
digestion with collagenase D. Cells were then stained with fl  uorescent 
antibodies to CD11c, CD3, and CD8α. The percentage of CD8α− and 
CD8α+ within the CD11c+CD3− subset was determined by fl  ow cytometry, 
and total numbers per spleen were quantifi  ed by relating the percentage of 
these cells to total numbers of CD11c+CD3− spleen cells. Histogram bars 
represent mean values ± SD for three mice per group. The experiment is 
representative of three similar experiments. Statistical analysis was per-
formed using the Student’s t test. *, P < 0.01; and **, P < 0.001.2468  IL-10R BLOCKADE RESOLVES CHRONIC VIRAL INFECTION | Ejrnaes et al.
associated with viral dissemination and replication. At this 
time, viral antigen could be detected by RT-PCR (unpublished 
data). Because we had previously observed that CD4+ T cells 
from LCMV clone 13–infected mice produced elevated 
  levels of IL-10, the isolated DCs were cultured for 5 d with 
naive GP61-80-specifi  c CD4+ responder T cells isolated from 
TCR transgenic SMARTA mice (52). No exogenous anti-
gen was added to the cultures to ensure that only viral anti-
gen processed in vivo was presented by the DCs. The ability 
of the diff   erent DC subsets to stimulate LCMV-  specifi  c 
CD4+ T cells was determined by measuring the concentra-
tion of cytokines in the supernatants by ELISA at the end of 
the culture period. To rule out any contamination caused by 
cytokine release by APCs, DCs were irradiated, and levels of 
both IL-10 and IFN-γ were measured in the supernatants of 
DC cultures devoid of T cells. These background levels were 
<1 pg/ml (unpublished data).
IL-10 production by antiviral CD4+ T cells was induced 
exclusively by DCs isolated from LCMV clone 13–infected 
mice and was preferentially mediated by the CD8α− DC 
subset (Fig. 5 A), an observation that was confi  rmed when the 
diff  erent DC subsets were loaded with LCMV GP61-80 pep-
tide (not depicted). Importantly, this corresponded to the 
time point at which CD8α+ DC numbers in LCMV clone 
13–infected mice started to decline (Fig. 4 B). These results 
suggest that when CD8α+ DCs are infected and killed, the 
remaining CD8α− DCs that are left to prime T cells induce 
IL-10 production instead of a potent antiviral response. In 
contrast, CD8α− or CD8α+ DCs isolated from mice infected 
with LCMV Armstrong induced little to no IL-10 produc-
tion by LCMV-specifi  c CD4+ T cells (Fig. 5 A), indicating 
that diff  erences between the two LCMV infections could 
merely reside in the type of cytokine responses induced. In 
vivo anti–IL-10R treatment completely abrogated the capac-
ity of CD8α− DCs to induce IL-10 secretion in CD4+ T cells 
(Fig. 5 A), indicating that signaling through the IL-10R was 
crucial for CD8α− DCs to induce IL-10.
Additionally, both CD8α− and CD8α+ DCs from 
LCMV clone 13– and LCMV Armstrong–infected mice 
were able to stimulate IFN-γ production by CD4+ T cells, 
whereas CD8α+ DCs induced higher amounts of IFN-γ 
than CD8α− DCs. Anti–IL-10R treatment did not have an 
eff  ect on IFN-γ production induced by the diff  erent DC 
subsets (Fig. 5 B).
Importantly, although the amount of IL-10 induced by 
CD8α− and CD8α+ DC subsets was dependent on the 
LCMV strain used (Fig. 5 A), the amount of IFN-γ was 
similar for both LCMV strains (Fig. 5 B). Therefore, the 
IL-10 to IFN-γ ratio was always signifi  cantly higher when 
DCs from LCMV clone 13–infected mice were used as 
APCs (Fig. 5 C).
Collectively, these data show that anti–IL-10R treat-
ment abolished CD8α− DC-mediated IL-10 production in 
responder T cells early after infection and decreased abso-
lute CD8α− DC numbers over time, thereby inducing a 
shift toward IFN-γ+ and Tc1/Th1 responses, enabling viral 
clearance. Our observations that anti–IL-10R antibody led 
to resolution of protracted infection, enhanced antiviral T 
cell responses, and abrogated the ability of CD8α− DCs to 
induce IL-10 in CD4+ T cells, in conjunction with ob-
served lower viral titers in mice defi  cient in IL-10, under-
scores the important role IL-10 plays in maintaining a 
chronic viral infection.
Figure 5.  Anti–IL-10R treatment abolishes IL-10 production 
by CD8𝗂− and CD8𝗂+ DC subsets, restoring a Tc1/Th1-favorable 
environment. Spleens were isolated and pooled from mice 7 d after 
infection with LCMV Armstrong or LCMV clone 13 or from LCMV clone 
13–infected mice treated with anti–IL-10R antibody at the time of in-
fection (8–10 mice per group). Splenocytes were depleted of CD3+ cells 
and enriched based on expression of CD11c using MACS microbeads. 
Next, the purifi  ed CD11c+ population was labeled with fl  uorescent anti-
bodies to CD11c and CD8α and sorted into CD11c+CD8α− (left) or 
CD11c+CD8α+ DCs (right) by fl  ow cytometry. The sorted DCs were ir-
radiated (2,900 rad), and 1.5 × 105 DCs from each subset were cultured 
in U-bottom 96-well plates in the presence of 6 × 105 GP61-80-specifi  c 
CD4+ T cells isolated from naive TCR transgenic SMARTA mice (refer-
ence 52). After 5 d, the concentration of IL-10 (A) and IFN-γ (B) present 
in the culture supernatants was measured by ELISA (pg/ml). No detect-
able IL-10 or IFN-γ was secreted by irradiated DCs alone (not depicted). 
Data was obtained from two independent experiments. Histogram bars 
represent mean values from one representative experiment ± SD from 
triplicate wells. (C) The results are depicted as the IL-10 to IFN-γ ratio 
to refl  ect the overall trend toward IL-10 production by the stimulated 
CD4+ T cells. Statistical analysis was performed using the Student’s 
t test. ***, P < 0.0001.JEM VOL. 203, October 30, 2006  2469
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DISCUSSION
This study is the fi  rst to report that inhibiting IL-10 signaling 
in vivo leads to enhancement of viral clearance in a mouse 
model of persistent viral infection. Our data demonstrate that 
upon challenge with LCMV clone 13, the strong antiviral 
response elicited early after infection rapidly subsides and is 
followed by a state of chronic infection associated with gen-
eralized lymphopenia. In this paper, we show that chronic 
infection and deterioration in health is associated with sys-
temic increase in the production of IL-10. Although the im-
plication for the role of IL-10 in the maintenance of chronic 
viral infections has hitherto been unclear, our results show 
that lymphopenia is reversed, bodyweight recovers, and viral 
load is signifi  cantly reduced upon blockade of IL-10–IL-10R 
signaling (P < 0.0001). Furthermore, we show that anti–IL-
10R treatment results in a reduction of CD8α− DC numbers 
and a subsequent abolishment of IL-10 production, thereby 
favoring a Tc1/Th1 cell–like environment inducing LCMV-
specifi  c IFN-γ+ T cell responses. Indeed, after LCMV clone 
13 infection, CD8α+ DC numbers substantially were found 
to decrease because of viral infection and clearance, and we 
now show that CD8α− DCs will preferentially induce IL-10 
production by T cells. Thus, it is possible that the generalized 
state of lymphopenia of LCMV clone 13–infected mice is 
mediated by APCs inducing IL-10–producing T cells, which 
results in a negative feedback loop. Our results suggest that 
distinct DC subsets may diff  erentially regulate the cytokine 
balance of the immune response in vivo. The precise mecha-
nism by which these DC subsets mediate their eff  ects might 
be related to levels of IL-10 present in the microenviron-
ment. We show that CD8α− DCs induce IL-10 production 
more effi   ciently than their CD8α+ counterparts. The ability 
to potentiate IL-10 secretion is drastically reduced upon 
blockade of signaling through the IL-10R. We believe that 
anti–IL-10R treatment modulates CD8α− DCs early upon 
infection and, as a result, dictates the nature of the cytokine 
response induced early during antiviral immunity.
The mechanisms by which IL-10 enables LCMV clone 
13 to persist are unknown. Several variables associated with T 
cell priming have been shown to be important and may pro-
gram qualitative diff  erences into the eff  ector and memory 
populations (53). IL-10 could either down-regulate proin-
fl  ammatory responses in a general manner or, more specifi  -
cally, inhibit the induction or expansion of antiviral CD8+ 
eff  ector T cells. Importantly, we report for the fi  rst time that 
anti–IL-10R antibody treatment reduces PD-1 expression on 
CD8+ T cells, which has previously been shown to contrib-
ute to virally induced CD8+ T cell exhaustion (33–36). In-
terestingly, stimulation through TLR2, which has been 
shown to bind to LCMV, leads to the production of IL-10 
and inhibits IFN-inducible protein 10 and IL-12 secretion by 
APCs. Thus, stronger binding of LCMV clone 13 to TLR2, 
as opposed to weaker TLR2 binding by LCMV Armstrong 
(54), could not only induce preferential production of IL-10 
by DCs but also inhibit the secretion of cytokines that pro-
mote DC diff  erentiation, maturation, and proliferation rather 
than survival (49). In addition, it is possible that the DCs that 
remain after LCMV clone 13 infection express higher levels 
of TLR2, thus perpetuating the cycle.
Subclasses of DCs have been shown to have the potential 
to diff  erentially skew T cell cytokine production toward Th1 
or Th2 cell profi  les (40, 41, 55). Notably, it has been sug-
gested that CD8α− DCs induce Th2 cell profi  les, whereas 
CD8α+ DCs preferentially stimulate IFN-γ production and, 
therefore, induce Th1 cell profi  les (39, 51). We now show 
that this may be true in the LCMV system, as we have ana-
lyzed the ability of CD8α− and CD8α+ DCs to polarize 
LCMV-reactive CD4+ T cells ex vivo. It appears that priming 
of cytotoxic T lymphocytes by DCs is achieved in a similar 
fashion in LCMV clone 13– and LCMV Armstrong–infected 
mice, but that stronger binding of LCMV clone 13 to its 
  receptor on APCs, particularly CD8α+ DCs, leads to more 
effi   cient processing and presentation of viral antigen. Our 
fi  nding that LCMV clone 13 infection leads to early in-
duction of IFN-γ–secreting LCMV-specifi  c CD8+ T cells 
strengthens this hypothesis. The strong cytotoxic function of 
such activated Tc1 or Th1 cells upon infection with LCMV 
clone 13 may result in killing of the APC subset responsible 
for their induction; i.e., DCs belonging to the CD8α+ sub-
set. This hypothesis correlates with our fi  nding that the num-
ber of CD8α+ DCs is reduced as early as day 7 after infection 
with LCMV clone 13 but not LCMV Armstrong.
Our results suggest that as the number of CD8α+ DCs 
decreases after chronic LCMV clone 13 infection, the CD8α− 
DC subset—which is more likely to prime T cells to produce 
IL-10 than Tc1/Th1 cytokines—will by default become the 
modulator of the T cell response. LCMV-specifi  c CD4+ T 
cells activated in this context may provide inappropriate or 
insuffi     cient antiviral help to other cell types, particularly 
CD8+ T cells, thus leading to persistent infection. Addition-
ally, it is possible that the CD8α− DCs, which appear ill-
equipped to propagate antiviral eff  ectors, will continue to 
support IL-10 production. The resulting high concentration 
of IL-10 in the milieu may thus lead to further modulation of 
DC function. In fact, IL-10 may directly decrease the viabil-
ity of CD8α+ DCs, as has been previously suggested (40, 56). 
As a result, only disruption of IL-10 signaling will have the 
ability to break the vicious circle and enable the recovery of 
appropriate antiviral immunity by the infected host.
Mechanistically, our fi  ndings show that anti–IL-10R anti-
body treatment lowers the endogenous levels of IL-10, re-
stores the ability to mount an antiviral CD8+ T cell response, 
and results in enhanced viral clearance, which all highlight the 
important role IL-10 plays in the maintenance of chronic 
infection. Upon treatment with anti–IL-10R, we observed 
a profound decrease in CD8α− and, to a lesser degree, in 
CD8α+ DC numbers, as well as a complete inability of CD8α− 
DCs to induce IL-10 production by CD4+ responder T cells, 
thereby favoring a systemic cytokine milieu that would better 
support IFN-γ+ and Tc1/Th1 cell responses.
Importantly, the inability of CD8α− DCs to induce IL-10 
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  underscores that IL-10 and signaling through the IL-10R 
is indeed involved in shaping the cytokine milieu with a po-
tential impact on immune responses. Our results imply that 
IL-10R blockade is of great interest for the therapeutic treat-
ment of chronic viral infections in humans.
MATERIALS AND METHODS
Mice, virus, and antibody treatment. 6-wk-old BALB/c, C57BL/6 
(B6), and IL-10−/− (B6 background) mice were purchased from The Jackson 
Laboratory. LCMV-GP61-80–specifi  c CD4+ TCR transgenic SMARTA mice 
(52) were obtained from S. Crotty (La Jolla Institute for Allergy and Immuno-
logy, La Jolla, CA) and housed under specifi  c pathogen-free conditions at the 
La Jolla Institute for Allergy and Immunology. LCMV plaques were purifi  ed 
three times on Vero cells, and viral stocks were prepared by a single passage 
on BHK-1 cells. Age-matched mice were infected i.v. with a single dose of 
either 2 × 106 PFU LCMV clone 13, 2 × 106 LCMV Armstrong, or an i.p. 
dose of 105 PFU LCMV Armstrong. For IL-10 blocking experiments, mice 
were injected i.p. with 250 μg anti–mouse IL-10R (1B1.3a; Becton Dickinson) 
monoclonal antibody or isotype control antibody (rat IgG1; BD Biosciences). 
All animal experiments were approved by the La Jolla Institute for Allergy 
and Immunology Animal Care Committee.
LCMV plaque assay. Organs (kidney, liver, spleen, and lung) were snap-
frozen, weighed, and homogenized. In brief, three diff  erent dilutions of 
homogenized organ were prepared, and triplicates were used. Dilutions 
were incubated at 37°C, 5% CO2 for 1 h with Vero cell monolayers grown 
in 6-well plates (Costar). The plates were then overlaid with 1% agarose 
in minimal essential medium 199 (Invitrogen) containing 10% FCS (Hy-
Clone) and incubated at 37°C, 5% CO2 for 5 d. The wells were treated 
with 25% formaldehyde and stained with 0.1% crystal violet for 2 min. 
The agarose overlay was removed, infectious centers were counted, and 
the counts were averaged. Additionally, viral LCMV stock was used as 
a positive control.
RT-PCR. A detailed version of this assay will be published elsewhere 
  (unpublished data). In brief, RNA was isolated from 50 μl of serum or 
10 mg of tissue samples using RNAqueous (Ambion). All samples were frozen 
at −80°C until RNA extraction. RNA was eluted in a volume of 20 μl, and 
purifi  ed RNA was frozen at −80°C until further use. 10 μl RNA was used 
in a 20-μl cDNA reaction with SuperScript III reverse transcriptase (Invitrogen) 
and a gene-specifi  c primer (GP-R, G  C  A  A  C  T  G  C  T  G  T  G  T  T  C  C  C  G  A  A  A  C  ). 
5 μl cDNA was used as template for a 25-μl quantitative real-time PCR re-
action on a GeneAmp 5700 (ABI), using primers GP-R and GP-F (C  A  T  T  C-
A  C  C  T  G  G  A  C  T  T  T  G  T  C  A  G  A  C  T  C  ). A standard curve was generated using 
pSG5-GP plasmid (57), a gift from J.C. de la Torre (Scripps Research Insti-
tute, San Diego, CA). Data were analyzed using linear regression analysis 
software (Prism; GraphPad).
Quantifi  cation of cytokines. Cytokine quantifi  cation was performed by 
sandwich ELISA of supernatants. 2–5 × 106 splenocytes were incubated for 
48 h in complete RPMI 1640 (Invitrogen) supplemented with 10% FCS 
(Sigma-Aldrich), 2 mM l-glutamine (Sigma-Aldrich), 50 μM 2-β-mercap-
toethanol (Sigma-Aldrich), and 5 mM Hepes (Sigma-Aldrich) in 24-well 
plates (Invitrogen). For the detection of IL-10–secreting cell subsets from in 
vitro infected cultures, bulk splenocytes were infected in vitro with LCMV 
Armstrong or LCMV clone 13 (multiplicity of infection = 3) without or 
with 10μg/ml anti–IL-10R antibody and incubated at 37°C in complete 
RPMI 1640. 48 h after infection, splenocytes were sorted into CD4+, CD8+, 
and CD11c+ populations by MACS, and equal numbers of each cell subset 
were incubated for 5 d at 37°C. Supernatant was removed at the time points 
indicated in the fi  gures, and ELISA was performed in accordance with the 
manufacturer’s recommendations and standardized with mouse recombinant 
cytokine (BD Biosciences). Plates were read at 405 nm (Spectra Max 250; 
Molecular Devices). The sensitivity of the IL-10 ELISA was 10 pg/ml. Data 
shown correspond to the concentration of IL-10 (pg/ml) per 106 cells.
Intracellular cytokine staining, cell surface staining, and fl  ow 
  cytometry. To detect cytokine-producing cell subsets, splenocytes from 
LCMV-infected BALB/c or B6 mice were stimulated with 1 μg/ml NP118-126, 
GP33-41, or GP61-80 peptide, respectively, in complete RPMI 1640 con-
taining Brefeldin A (BFA; Sigma-Aldrich) at 37°C. 6 h later, cells were 
  resuspended in staining buff  er containing 1% FCS and 0.2% NaN3, labeled 
with anti-CD4 and anti-CD8, fi  xed in 1% paraformaldehyde, and permeabi-
lized with 0.1% saponin buff  er. Intracellular staining was performed with 
  fl  uorescent antibodies to IFN-γ, TNF-α, or isotype controls. All antibodies 
were obtained from BD Biosciences. Additionally, PD-1 expression was de-
tected on splenocytes by labeling with an anti–PE-conjugated PD-1 antibody 
(eBioscience). Events were acquired using a fl  ow cytometer (FACSCalibur; 
Becton Dickinson) and analyzed using software (CellQuest; Becton Dickin-
son). 1–2 × 104 events were acquired, and live cells were gated based on for-
ward/side scatter properties. When analyzing CD11c+ subsets, CD3-expressing 
cells were gated out to avoid contamination by T cells expressing myeloid 
markers (58, 59), and expression of the indicated cell surface molecules was 
detected on CD11c+ and CD8α+/− cells. The number of cells was calculated 
by relating the frequency of cells from each subset to the overall number of 
cells per spleen.
Sorting of CD11c+CD8𝗂− and CD11c+CD8𝗂+ cells. Splenocytes 
from mice infected 7 d earlier with LCMV Armstrong or LCMV clone 13 
with or without anti–IL-10R antibody treatment were incubated with 
HBSS medium containing 0.5 mg/ml collagenase D (Sigma-Aldrich) at 
37°C, 5% CO2 for 30 min. 0.01 M EDTA was added to disrupt T cell–DC 
complexes. Next, cells were depleted of CD3-expressing cells (Dynal CD3-
beads; Dynal), incubated with CD11c microbeads (Miltenyi Biotec), and 
positively selected using MACS columns. The enriched CD11c+ cells were 
labeled with APC-conjugated CD11c and PE-conjugated CD8α antibody 
(BD Biosciences) and sorted using a cell sorter (FACS Aria; Becton Dickinson) 
into CD8α− and CD8α+ CD11c+ subsets. 1.5 × 105 sorted CD11c+ cells 
were placed in 96-well plates in complete RPMI 1640 medium and irra-
diated with 2,900 rad. Assessment of the polarization of antigen-specifi  c 
CD4+ T cells by DCs ex vivo was adapted from a previously described 
method (60). LCMV GP61-80-specifi  c CD4+ T cells isolated from TCR 
transgenic SMARTA mice (52) were purifi  ed by negatively depleting CD8-, 
B220-, and CD11b-expressing cells with Dynal beads and, after enrichment 
of CD4+ T cells, with CD4-MACS beads (purity > 98%). 6 × 105 CD4+ 
cells were added to DCs in the presence or absence of 1 μg/ml GP61-80 
  peptide. Supernatants were isolated 5 d later and analyzed for the presence 
of IL-10 and IFN-γ by ELISA, as reported earlier in this paper.
Statistical analysis. Statistical analyses were performed using the Student’s 
t test: *, P < 0.01; **, P < 0.001; and ***, P < 0.0001.
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